Med24
peptide-development 23. 10. 2026 • 2 min read • Diabetes, metabolic syndrome and obesity : targets and therapy

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

Israelin lääkärimissio – uudet politiikat ja ratkaisut terveydenhuollon haasteisiin.

Polycystic ovary syndrome, now termed polyendocrine metabolic ovarian syndrome (PMOS), is a global condition affecting 170 million women and frequently associated with obesity and insulin resistance. Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP agonists, represent a potential approach to addressing metabolic dysfunction within this population. Research examines the impact of these therapies on anthropometric and metabolic parameters in women of reproductive age, considering specific challenges related to preconception planning, treatment duration, and post-discontinuation management.

Key Clinical Findings

Clinical trial evidence indicates that liraglutide, semaglutide, and tirzepatide produce reductions in body weight, body mass index (BMI), and waist circumference. Some studies have observed preferential effects on visceral and ectopic fat. Glycemic and insulin resistance outcomes demonstrate variability across studies. Lipid and blood pressure effects have not been fully characterized.

Sponsored content

Further Research Needs

Available evidence suggests that higher-potency agents may offer more consistent weight-loss benefits. However, current research does not establish comparative metabolic superiority among the agents within the PMOS population. Interpretation of the data is limited by short-term trials at sub-obesity doses, frequent co-administration with metformin, and a lack of phenotype-stratified data. Larger, longer, and higher-dose trials are required to comprehensively define the anthropometric and metabolic potential of these therapies in women with PMOS.

Original Scientific Source
Diabetes, metabolic syndrome and obesity : targets and therapy
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity
peptide-development

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity

Aims Glucagon-like peptide-1 (GLP-1) receptor agonist-based medicines are highly effective treatments for overweight and obesity, but population-scale real-world evidence remains limited, particularly in self-funded settings where treatment choice may be influenced by relative price. We aimed to characterise provider...

14. 10. 2026 Read article →
Advertisement